Literature DB >> 22702956

Low dose proteasome inhibition affects alternative splicing.

Sven Bieler1, Elke Hammer, Manuela Gesell-Salazar, Uwe Völker, Karl Stangl, Silke Meiners.   

Abstract

Protein degradation by the ubiquitin proteasome system ensures controlled degradation of structural proteins, signaling mediators, and transcription factors. Inhibition of proteasome function by specific proteasome inhibitors results in dose-dependent cellular effects ranging from induction of apoptosis to protective stress responses. The present study seeks to identify nuclear regulators mediating the protective stress response to low dose proteasome inhibition. Primary human endothelial cells were treated with low doses of the proteasome inhibitor MG132 for 2 h, and proteomic analysis of nuclear extracts was performed. Using a 2-D differential in gel electrophoresis (DIGE) approach, we identified more than 24 splice factors to be differentially regulated by low dose proteasome inhibition. In particular, several isoforms of hnRNPA1 were shown to be increased, pointing toward altered posttranslational modification of hnRNPA1 upon proteasome inhibition. Elevated levels of splice factors were associated with a different alternative splicing pattern in response to proteasome inhibition as determined by Affymetrix exon array profiling. Of note, we observed alternative RNA processing for stress associated genes such as caspases and heat shock proteins. Our study provides first evidence that low dose proteasome inhibition affects posttranscriptional regulation of splice factors and early alternative splicing events.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22702956     DOI: 10.1021/pr300435c

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  3 in total

1.  The Splicing Factor hnRNPA1 Regulates Alternate Splicing of the MYLK Gene.

Authors:  Joseph B Mascarenhas; Alex Y Tchourbanov; Sergei M Danilov; Tong Zhou; Ting Wang; Joe G N Garcia
Journal:  Am J Respir Cell Mol Biol       Date:  2018-05       Impact factor: 6.914

2.  Biosignatures for Parkinson's disease and atypical parkinsonian disorders patients.

Authors:  Judith A Potashkin; Jose A Santiago; Bernard M Ravina; Arthur Watts; Alexey A Leontovich
Journal:  PLoS One       Date:  2012-08-27       Impact factor: 3.240

3.  C9ORF72, implicated in amytrophic lateral sclerosis and frontotemporal dementia, regulates endosomal trafficking.

Authors:  Manal A Farg; Vinod Sundaramoorthy; Jessica M Sultana; Shu Yang; Rachel A K Atkinson; Vita Levina; Mark A Halloran; Paul A Gleeson; Ian P Blair; Kai Y Soo; Anna E King; Julie D Atkin
Journal:  Hum Mol Genet       Date:  2014-02-18       Impact factor: 6.150

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.